Rudolf Stadler, MD, PhD, University Medical Center Minden, Minden, Germany, shares an overview of novel therapies which are currently under investigation for the treatment of cutaneous T-cell lymphoma (CTCL), highlighting the antibody therapy lacutamab which has demonstrated promising early results in the treatment of Sézary syndrome and mycosis fungoides. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.